NEO:CYBN
NEO:CYBN

Slide play_arrow Watch The Video About Cybin. A leading biotechnology company focused on progressing psychedelic therapeutics. Slide Read More Company Highlights We are focused, experienced and well resourced in developing:

Robust drug discover platform rooted in psychedelic compounds

Proprietary delivery & formulations for improved dose control & efficacy on-set/off-set

Novel Treatment protocols for enriched patient lifecycle management.
Read Morearrow_forward_ios
Slide Our Team Our medical team has over 300 combined publications in mental health and psychedelics. Led by a management team that has facilitated billions in pharmaceutical sales and successfully developed multiple drugs (Allegra, Sabril, Anzemet, Vaniqa).

Seasoned CEO with over 30 years in healthcare, having raised over US$4B in capital and led over US$5B in M&A activity.
Read More arrow_forward_ios
Slide Cybin x kernel Partnership Cybin will leverage Kernel’s flow to quantify brain activity during psychedelic experiences in real time, adding an exciting dimension to its investigative work focused on developing breakthrough therapeutics for mental health disorders. Read More arrow_forward_ios

Slide play_arrow Watch The Video A leading biotechnology company focused on progressing psychedelic therapeutics. Slide
Read More
Company Highlights Robust drug discovery platform rooted in psychedelic compounds

Proprietary delivery & formulations for improved dose control & efficacy on-set/off-set

Novel treatment protocols for enriched patient lifecycle management.
Read Morearrow_forward_ios
Slide
Read More
Our Team Our medical team has over 300 combined publications in mental health and psychedelics. Led by a management team that has facilitated billions in pharmaceutical sales and successfully developed multiple drugs (Allegra, Sabril, Anzemet, Vaniqa).

Seasoned CEO with over 30 years in healthcare, having raised over US$4B in capital and led over US$5B in M&A activity.
Read More arrow_forward_ios
Slide Read More Cybin x kernel Partnership Cybin will leverage Kernel’s flow to quantify brain activity during psychedelic experiences in real time, adding an exciting dimension to its investigative work focused on developing breakthrough therapeutics for mental health disorders. Read More arrow_forward_ios

Sign up to receive the latest news on Cybin.